Pirepemat (IRL752) is being developed to improve balance and reduce falls, and thus injuries from falls, in people living with Parkinson’s. Falls are a significant consequence of Parkinson’s that has severe complications, such as fractures, impaired mobility and reduced quality of life. Impaired balance and falls are linked to cognitive decline and the progression of Parkinson’s disease.
Written by
nednedned
To view profiles and participate in discussions please or .
Pirepemat (IRL752) is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat (IRL752) is used for the study of Parkinson's disease.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.